Press Releases

Press Releases
Date Title and Summary View
Nov 21, 2017 Presentations will focus on a wide range of disease areas including multiple myeloma, lymphoma, acute myeloid leukemia, myelodysplastic syndromes and beta-thalassemia and novel technologies such as CAR-T cell therapy SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) ...
Nov 21, 2017 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) plans to webcast an analyst and investor event being held at the American Society of Hematology (ASH) meeting in Atlanta on December 10. The webcast will begin at 8pm ET and will be available in the Investor Relations section of the Company's ...
Nov 16, 2017 Designations based on preliminary clinical data from ongoing phase I study of bb2121 in heavily pre-treated multiple myeloma SUMMIT, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) and bluebird bio, Inc. (NASDAQ:BLUE) today announced that bb2121, a chimeric antig...
Nov 1, 2017 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced the successful pricing of three series of senior unsecured notes for an aggregate principal amount of $3,000 million. Of these notes, $750 million will mature in 2023 and will bear interest at an annual rate of 2.750 percen...
Oct 31, 2017 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) today announced its intention to offer, subject to market and other conditions, senior unsecured notes under a shelf registration statement on Form S-3 on file with the Securities and Exchange Commission. The interest rate, the maturity d...
Oct 28, 2017 Ozanimod demonstrated superiority versus interferon beta-1a (Avonex®) in reducing annualized relapse rates and MRI brain lesions at two years Incidence of adverse events and serious adverse events similar to Avonex Safety and tolerability profile consistent with prior phase II...
Oct 27, 2017 Ozanimod demonstrated superiority versus interferon beta-1a (Avonex®) in reducing annualized relapse rates and MRI brain lesions Incidence of adverse events and serious adverse events similar to Avonex Safety and tolerability profile consistent with prior phase II studies ...
Oct 27, 2017 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) plans to present at three upcoming investor conferences where Celgene management will provide an overview of the Company. The conferences will be webcast live and will be available in the Investor Relations section of the Company's website at www....
Oct 26, 2017 - Updating 2017 guidance and financial targets for 2020 - Data from multiple next generation growth drivers being presented at 14 major global medical meetings in Q4 including ECTRIMS, UEGW and ASH SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) reported net...
Oct 19, 2017 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) today announced that the GED-0301 (mongersen) phase III REVOLVE trial (CD-002) in Crohn's disease (CD) and the extension trial (SUSTAIN, CD-004) will discontinue. Celgene has decided to stop the trials following an October recommendation of the ...
1
... NextLast
Add to Briefcase = add release to Briefcase